Number of the records: 1
Epoxylipids and soluble epoxide hydrolase in heart diseases
- 1.
SYSNO ASEP 0556810 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Epoxylipids and soluble epoxide hydrolase in heart diseases Author(s) Imig, J. D. (US)
Červenka, L. (CZ)
Neckář, Jan (FGU-C) RID, ORCIDArticle number 114866 Source Title Biochemical Pharmacology. - : Elsevier - ISSN 0006-2952
Roč. 195, Jan (2022)Number of pages 9 s. Language eng - English Country US - United States Keywords eicosanoids ; cytochrome P450 ; soluble epoxide hydrolase ; hypertension ; heart failure ; myocardial infarction ; inflammation ; mitochondrial function ; coronary artery OECD category Physiology (including cytology) R&D Projects GA18-03207S GA ČR - Czech Science Foundation (CSF) Method of publishing Limited access Institutional support FGU-C - RVO:67985823 UT WOS 000777271600005 EID SCOPUS 85120733144 DOI 10.1016/j.bcp.2021.114866 Annotation Cardiovascular and heart diseases are leading causes of morbidity and mortality. Coronary artery endothelial and vascular dysfunction, inflammation, and mitochondrial dysfunction contribute to progression of heart diseases such as arrhythmias, congestive heart failure, and heart attacks. Classes of fatty acid epoxylipids and their enzymatic regulation by soluble epoxide hydrolase (sEH) have been implicated in coronary artery dysfunction, inflammation, and mitochondrial dysfunction in heart diseases. Likewise, genetic and pharmacological manip-ulations of epoxylipids have been demonstrated to have therapeutic benefits for heart diseases. Increasing epoxylipids reduce cardiac hypertrophy and fibrosis and improve cardiac function. Beneficial actions for epox-ylipids have been demonstrated in cardiac ischemia reperfusion injury, electrical conductance abnormalities and arrhythmias, and ventricular tachycardia. This review discusses past and recent findings on the contribution of epoxylipids in heart diseases and the potential for their manipulation to treat heart attacks, arrhythmias, ven-tricular tachycardia, and heart failure. Workplace Institute of Physiology Contact Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Year of Publishing 2023 Electronic address https://doi.org/10.1016/j.bcp.2021.114866
Number of the records: 1